Abacavir
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Abacavir and local guidelines before prescribing.
Nucleoside analogue antiviral
Mechanism
Nucleoside reverse transcriptase inhibitor.
Uses
HIV infection.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Hypersensitivity reaction (HLA-B*5701), nausea, cardiovascular risk, fever.
Interactions
Alcohol raises levels.
Contraindications and cautions
HLA-B*5701 positive, severe liver impairment
Monitoring
HLA-B*5701, LFT
Pregnancy and breastfeeding
Acceptable
Renal and hepatic impairment
Avoid in moderate to severe hepatic impairment
Overdose and reversal
Supportive
Special advice
HLA-B*5701 test before starting; never rechallenge after hypersensitivity.
More from the textbook: uses, cautions and other points
- Important examples : Gene Drug Effect TPMT (and NUDT15) Azathioprine, mercaptopurine Low activity → severe bone marrow suppression - test before starting DPYD 5-fluorouracil, capecitabine Deficiency → severe, potentially fatal toxicity - test before starting (UK standard) HLA-B*57:01 Abacavir (HIV) Hypersensitivity reaction - test before …
Clinical pharmacology and prescribing: Principles of clinical pharmacology - 🧬 Prenatal and newborn screening, pharmacogenomics and ethics - page 6 of the Clinical Genetics chapter. Every pregnant woman in the UK is offered genetic screening, and every newborn has a blood spot test - so all doctors need to explain these tests and their results. Pharmacogenomics is now part of everyday prescribing (DPYD before …
Clinical Genetics: Prenatal and newborn screening, pharmacogenomics and ethics - NRTIs | Tenofovir (disoproxil or alafenamide), emtricitabine, lamivudine, abacavir | Tenofovir disoproxil - kidney tubular damage (Fanconi), bone loss (alafenamide less so); tenofovir, emtricitabine and lamivudine also treat hepatitis B (stopping can cause a hepatitis flare); abacavir - severe hypersensitivity in people with HLA-B*57:01 …
ID: HIV, viral hepatitis and blood-borne viruses - Abacavir | Test HLA-B*57:01 first - hypersensitivity.
ID: HIV, viral hepatitis and blood-borne viruses - Rash and fever 1 week after starting abacavir | Abacavir hypersensitivity (HLA-B*57:01)
ID: HIV, viral hepatitis and blood-borne viruses - Test HLA-B*57:01 before abacavir.
ID: HIV, viral hepatitis and blood-borne viruses - HLA-B*57:01 | Abacavir (HIV) | Hypersensitivity reaction - test before starting
Clinical pharmacology and prescribing: Principles of clinical pharmacology - Pharmacogenomic tests before azathioprine (TPMT), fluorouracil (DPYD), abacavir (HLA-B*57:01) and carbamazepine in some ancestries (HLA-B*15:02).
Clinical pharmacology and prescribing: Principles of clinical pharmacology
Where it is discussed in the book
- ID: HIV, viral hepatitis and blood-borne viruses (4 mentions)
- Clinical pharmacology and prescribing: Principles of clinical pharmacology (3 mentions)
- Clinical pharmacology and prescribing: Adverse drug reactions, interactions and drug allergy (1 mention)
- Clinical Immunology: Immune system basics and immunological investigations (1 mention)
- Clinical Genetics: Prenatal and newborn screening, pharmacogenomics and ethics (5 mentions)
- Biochemistry: Enzymes, vitamins and trace elements (1 mention)
- Microbiology: Virology - structure, replication and important viral infections (2 mentions)
- Pathology: Immunopathology, amyloidosis, genetic and environmental disease (1 mention)